ACHE and systemic lupus erythematosus: Centrally-acting mAChR agonists and acetylcholinesterase inhibitors have shown promising efficacy in murine models of sepsis, inflammatory bowel disease, obesity, lupus, and other conditions (Munyaka et al., 2014; Ji et al., 2014; Pham et al., 2018; Rosas-Ballina et al., 2015; Satapathy et al., 2011; Yang & Yang, 2018; Hanes et al., 2015) (Fig. 2).